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Abstract
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This study describes the antibacterial properties of synthetically-produced mixed aryl alkyl disulfide
compounds as a means to control the growth of Staphylococcus aureus and Bacillus anthracis. Some
of these compounds exerted strong in vitro bioactivity. Our results indicate that among the twelve
different aryl substituents examined, nitrophenyl derivatives provide the strongest antibiotic
activities. This may be the result of electronic activation of the arylthio moiety as a leaving group
for nucleophilic attack on the disulfide bond. Small alkyl residues on the other sulfur provide the
best activity as well, which for different bacteria appears to be somewhat dependent on the nature of
the alkyl moiety. The mechanism of action of these lipophilic disulfides is likely similar to that of
previously reported N-thiolated β-lactams, which have been shown to produce alkyl-CoA disulfides
through a thiol-disulfide exchange within the cytoplasm, ultimately inhibiting type II fatty acid
synthesis. However, the mixed alkyl-CoA disulfides themselves show no antibacterial activity,
presumably due to the inability of the highly polar compounds to cross the bacterial cell membrane.
These structurally simple disulfides have been found to inhibit β-ketoacyl-acyl carrier protein
synthase III, or FabH, a key enzyme in type II fatty acid biosynthesis, and thus may serve as new
leads to the development of effective antibacterials for MRSA and anthrax infections.
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1. Introduction
The design of new antimicrobial agents has reached unprecedented urgency as drug resistance
in certain medically-relevant bacteria continues to climb. Our laboratory has recently been
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investigating the microbiological properties of N-alkylthio β-lactams1–9 and N-alkylthio-2oxazolidinones10 (Figure 1) as potential antibiotics for treatment of infections caused by
methicillin-resistant Staphylococcus aureus (MRSA) and Bacillus anthracis (the causative
agent of anthrax).
These compounds exert selective bacteriostatic properties against Staphylococcus and
Bacillus microbes over most other common bacterial genera, and demonstrate unique structureactivity profiles never seen before for β-lactam and 2-oxazolidinone antibiotics. One of the
structural requirements of these compounds is that the residues on the heterocyclic ring and
sulfur side chain must be highly lipophilic in order to bestow the most potent antibacterial
activities. Most recently our studies have determined that N-methylthio β-lactams block type
II fatty acid biosynthesis in S. aureus through the initial transfer of the N-alkylthio moiety from
the ring nitrogen onto a cellular target. 9 We have since identified this target as being coenzyme
A (CoASH), which is present in large quantities in the cytoplasm and comprises the redox
buffer system of these bacteria. It is postulated that sulfenylation of coenzyme A produces an
alkyl-CoA disulfide (CoASSR) responsible for inhibiting lipid biosynthesis (Scheme 1).
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Recent work in the Reynolds laboratory has demonstrated that these mixed alkyl-CoA
disulfides, CoASSR, covalently modify the fatty acid biosynthesis protein, FabH, and that the
inhibitory effects are highly dependent on the nature of the alkyl side chain R.11 In our initial
investigations, we examined the possibility that the CoASSR disulfides could directly inhibit
microbial growth if fed to bacteria growing in culture media. However, incubation of S.
aureus cells with CoASSMe does not lead to growth inhibition, as judged by both Kirby-Bauer
disk diffusion studies and minimum inhibitory concentration assays in broth. Although this
seemed surprising at first, given that this compound is likely responsible for bioactivity in the
cell, this suggests that the multiply charged CoA moiety may not easily traverse the cell
membrane to be able to exert an inhibitory effect within the cytoplasm.12 This led to the
realization that the N-thiolated β-lactam, and presumably the N-thiolated oxazolidinone as well,
may have the requisite cell permeability and sulfenylation capabilities for antibacterial activity,
and could generate the CoASSR adduct intracellularly. Since it was apparent that the lactam
or the oxazolidinone rings did not have any special structural features needed for activity, other
than being relatively lipophilic and able to serve as a leaving group during nucleophilic attack
on sulfur, we thought we could utilize lipophilic disulfides in place of the N-thiolated β-lactams
as a means to delivery electrophilic sulfur species more effectively into the bacterial cell. In
fact, nature has long used disulfides and trisulfides as natural sulfenylation agents, as evidenced
by the large number of naturally-occurring compounds that have anti-infective properties.13
Highly notable examples include diallyl disulfide, diallyl trisulfide, ajoene, Sallylmercaptocysteine, and allicin, found only in freshly crushed garlic (Figure 2).14–17 The
biological targets and mode of action of most of these compounds are not precisely known,
but in the case of allicin, there are distinct similarities in the antibiotic properties to the Nthiolated β-lactams (and N-thiolated oxazolidinones). In addition to exhibiting activity against
a wide range of bacteria18–21, allicin possesses antifungal22–24, antiviral25,26,
antiparisitic27,28, and anticancer properties. Both the lactams and allicin strongly inhibit fatty
acid synthesis29–32, but also partially inhibit protein and nucleic acid biosynthesis.33 Both
compounds exert their strongest antibacterial activities against microbes such as S. aureus and
B. anthracis that express unusually low levels of glutathione and relatively high levels of
coenzyme A. Allicin reacts with sulfhydryl residues of various proteins such as RNA
polymerase, thioredoxin reductase, and alcohol dehydrogenase, and reversibly inhibits acetylCoA synthetases.34,35 This certainly suggests similar modes of action in causing intracellular
sulfenylation of their biological targets. A survey of the patent literature also uncovered two
recent U.S. patent applications describing the effects of mixed alkyl disulfides as inhibitors of
redox buffers in mammalian cells as a means to restore normal cellular function, a feature
attributed to their high reactivity towards and inhibition of thioredoxin.36,37
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To initiate these investigations, a selection of unsymmetrical aryl methyl disulfides was
synthesized from commercially-available arylthiols as shown in Scheme 2. We selected a group
of electronically-diverse arylthiols as coupling partners in this reaction to obtain aryl methyl
disulfides 1–8 for evaluation. The synthesis was done simply by combining a methanolic
solution of the aryl thiol (100 mL of 1.0 M) with a slight excess of the alkyl
methanethiolsulfonate (105 mL of 1.0 M methanolic solution) and stirring under an inert
atmosphere for 1 hour. The solutions were then treated with a small amount (about 0.3 eq.) of
cysteine hydrochloride to consume the excess methanethiolsulfonate. The solution was
concentrated and taken up in dichloromethane (1 mL), filtered to remove any cysteine products,
treated with Amberlyst 21resin (weakly basic), then flushed through a small silica plug to
remove impurities. In most instances, this yielded products >90% pure by 1H NMR. Yields
for these reactions were in most cases high and the disulfides were used in microbiological
screening assays without further purification. We carried out initial antibacterial assays on
these eight aryl methyl disulfides against methicillin-susceptible Staphylococcus aureus by
Kirby-Bauer disk diffusion on agar plates, according to National Committee for Clinical
Laboratory Standards guidelines.38 In each case, 20 µg of the test compound in DMSO was
applied to 6-mm wide wells bored directly into the agar, prior to inoculation and incubation.
The average zones of growth inhibition (from three trials) produced by the compounds after
24 h of incubation at 37 °C are presented in Table 1. The Kirby-Bauer data indicates that most
of the disulfides have weak or no antimicrobial activity, which suggests that the disulfide bond
itself is not enough of a prerequisite to induce antibacterial activity. Of these eight compounds,
the p-nitrophenyl analogue 8 showed the strongest in vitro activity against S. aureus, with zones
sizes comparable to some of our previously reported N-thiolated β-lactam compounds.3–8
We then expanded on the structure-activity properties of these compounds by making structural
modifications to the most potent one, aryl disulfide 8. These include changing the location of
the electron-withdrawing nitro group on the phenyl ring, as well as the length and branching
of the S-alkyl substituent. The same procedure shown in Scheme 1 was used to prepare metanitrophenyl disulfides 9 and ortho-nitrophenyl disulfides 10, employing the corresponding
alkylthio sulfonates as sulfenylating agents.
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Antimicrobial screening was done by Kirby-Bauer testing as well as by determining the
minimum inhibitory concentration (MIC) values of compounds 8–10 by broth serial dilution.
The data shown in Table 2 indicates that all three nitrophenyl disulfide systems were active
against S. aureus and B. anthracis, but it appeared that p-nitrophenyl disulfides 8 and m-nitro
isomers 9 were both considerably more active than the o-nitro analogues 10. The enhanced
bioactivity of these nitrophenyl disulfides compared to other aryl-substituted analogues
suggests that nucleophilic scission of the disulfide linkage is enhanced by strong electrondeficiency on the sulfur centers.
These data revealed that increasing the alkyl chain length of the aryl alkyl disulfide from methyl
to ethyl to propyl to butyl increased bioactivity somewhat, but not as much as introducing
branching in the chain (Table 2). Thus, the isopropyl disulfides and sec-butyl, 8c and 8d,
respectively, were considerably more active than the unbranched side chain analogues.
Additionally, all of the compounds appeared to be somewhat more active against S. aureus
than MRSA, which is opposite to what we observed previously for the N-thiolated β-lactams.
7 We do not believe this difference has anything to do with penicillinase production in MRSA,
since repeating the testing of S. aureus in the presence of penicillinase protein does not cause
a reduction in bioactivity.
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The most active series of compounds, p-nitrophenyl disulfides 8a–f, was also tested against
E. coli (K12 strain, ATCC 23590) (Table 3). With the lowest MICs being around 16 ug/ml,
none of these derivatives were appreciably active against E. coli. However, it is interesting that
the methyl and ethyl disulfides possess the strongest activity, which drops off dramatically as
the alkyl chain is elongated or branched. This is opposite to that observed for S. aureus and B.
anthracis.
The need for an aryl moiety directly on one of the sulfurs was made apparent when we tested
p-nitrobenzyl- and p-nitrophenethyl disulfides, 11 and 12 (Figure 3). Neither of these
compounds showed antibacterial activity against S. aureus, but had very weak activities against
B. anthracis (MICs of 32 and 64 ug/mL, respectively). Thus, insertion of a methylene or
ethylene group between the aryl ring and sulfur center dramatically reduces antibacterial
activity, probably due to significantly lower reactivity of the disulfide toward nucleophilic
displacement.
Likewise, the corresponding sulfide 13 and Ellman’s reagent (14) were both found to be
effectively inactive against S. aureus, illustrating the need for both a disulfide linkage (in the
case of inactive compound 13) and high lipophilicity (in the case of inactive disulfide 14) for
antimicrobial activity (Figure 4).
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In addition to the in vitro properties, we were interested to determine if the antibacterial activity
of the disulfides could be due to inhibition of a key enzymatic step in lipid biosynthesis in
bacteria. Given our recent finding that N-thiolated lactams react with coenzyme A to create a
mixed CoA disulfide and inhibits fatty acid biosynthesis, we decided to investigate whether
the disulfides could directly inhibit β-ketoacyl-acyl carrier protein synthase III, or FabH, a key
enzyme in type II fatty acid biosynthesis. Thus, additional experiments using compounds 8a–
f to determine inhibition capabilities against purified E. coli FabH verify that the disulfides are
highly active against this enzyme. This was carried out as described previously.39 Each
compound in this series showed >90% inhibition of E. coli FabH at a disulfide concentration
of 5 µM (Table 4).
For comparison, N-alkylthio β-lactams 15a and 15b were also tested, and both of these
thiolating lactams exhibited inhibitory activity against purified E. coli FabH (Figure 5). At 1
µM, methylthio lactam 15a inhibits FabH catalytic activity by 89%, while sec-butylthio lactam
15b induces a 30% decrease in activity. These assays were done in the absence of coenzyme
A, thus showing that the compounds directly act on FabH protein.

NIH-PA Author Manuscript

These results provide the first evidence that the disulfides and the N-alkylthio β-lactams can
inhibit bacterial growth in the same manner, directly through FabH inactivation. It should be
mentioned, however, that once inside the bacterial cell, the disulfides and N-alkylthio β-lactams
can exert indirectly inhibit FabH catalysis by readily forming alkyl-CoA mixed disulfide
adducts, which in turn can impede FabH function. Indeed, Reynolds has previously reported
that methyl-CoA mixed disulfide effectively inhibits E. coli-expressed FabH (IC50 = 57 µM).
11 Data is not yet available for inhibition studies on FabH from S. aureus.
It is noteworthy that the trends in activity observed for the nitrophenyl disulfides 8–10 coincide
with previous observations on the relative dimensions of the active site in each of the microbial
species studied. The active site of the E. coli FabH has been reported to preferentially bind Sacetyl CoA over larger or branched acyl CoA analogs.40 By contrast, the FabH from both
Staphylococcus41 and Bacillus42 have larger active site pockets, which favor reactions with
branched acyl-CoA species such as isobutyryl-CoA.43 These trends are followed precisely in
the bioactivities of the disulfide series, providing strong indirect evidence that these compounds
may selectively bind to FabH in a mechanism-based manner. One possibility is that the aryl
alkyl disulfides may inhibit FabH by reversibly “capping” the active site cysteine through a
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thiol-disulfide exchange. The reported X-ray crystal structures44,45 of FabH from S. aureus
indicates a fairly deep, lipophilic “pocket” into which acyl-CoA or acyl-ACP are able to stretch
their lipophilic arm during binding. A proximal cysteine residue is located within the active
site, and it is this available thiol that we speculate may be sulfenylated by entry of the aryl alkyl
disulfides into the enzyme. Reynolds has recently reported that the asymmetric disulfide 16
inhibits the activity of M. tuberculosis and E. coli FabH enzymes, by capping an active site
cysteine thiol by sulfenylation, and that this capping destroys catalytic functioning of the
enzyme (Figure 5). We presume that a similar event could be occurring intracellularly in the
FabH protein of S. aureus in the presence of the disulfides.46

3. Conclusions
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The aryl alkyl disulfides examined in this initial study possess strong in vitro antimicrobial
properties against S. aureus (including MRSA) and B. anthracis, and only weak activity against
E. coli. Of the structural variants included in our study, the nitrophenyl alkyl disulfides exhibit
the greatest in vitro potency. Perhaps even more interestingly, it seems that the efficacy of these
compounds may be “tuned” to select for a particular bacterial species: for E. coli, the methyl
aryl disulfides are optimal, while for Staphylococcus and Bacillus, the isopropyl- and sec-butyl
aryl disulfides appear to be more efficacious. The fact that the in vitro microbiological
properties of these compounds, determined from agar diffusion and agar MIC measurements,
coincides with the FabH inhibition capabilities certainly points to the fact that this key enzyme
is associated with the biological properties of the compounds. These results also highlight the
fact that the N-thiolated β-lactams (and presumably N-thiolated oxazolidinones), reported
previously as selective bacteriostatic agents for Staphylococcus and Bacillus, may act similarly
by directly inhibiting FabH protein in MRSA and B. anthracis.
The structural effects on bioactivity of these compounds raise several key questions regarding
the role of the aryl nitro substituent, whether it can be satisfactorily substituted for other
functionalities (such as water solubilizing groups), and if the aryl ring substituent in some way
aids in specific binding of the molecule to the FabH active site prior to sulfenylation.
Understanding the ability of alkyl-CoA mixed disulfides to covalently deactivate bacterial fatty
acid synthesis represents a major advance in the quest for novel antibacterials. However, due
to the demonstrated inability of CoA mixed disulfides to traverse the cell membrane, the alkylCoA disulfides are not directly useful as therapeutics. This research shows that prodrugs such
as the described disulfides and the previously reported N-alkylthio β-lactams can be used to
produce the CoA mixed disulfides within the bacterial target.
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The activity of methyl-CoA disulfide against ecFabH provides strong evidence that in
prokaryotic cells which contain CoA, the alkyl-aryl disulfides and N-alkylthio β-lactams may
function as prodrugs to produce alkyl-CoA disulfides, and that these mixed disulfides can then
inhibit the fatty acid cycle through inhibition of FabH. This mechanism is unique in that it
involves a thiol-disulfide exchange from the alkyl-CoA disulfide to the active-site cysteine of
FabH, a suggestion that is supported by protein crystallographic studies. Reynolds reported an
X-ray crystal structure of E. coli FabH showing the methylthio group from methyl-CoA
disulfide being covalently bound to the active site cysteine (112Cys). While the catalytic activity
of the methylthiolated (deactivated) FabH protein could not be regenerated simply by dialysis,
treatment with dithiothreitol (DTT) quickly restores full catalytic function. This suggests that
formation of the cysteine-alkyl FabH disulfide (either via the alkyl-CoA disulfide, the alkylaryl disulfide, or N-alkylthio β-lactam) is irreversible under buffered aqueous conditions, but
that addition of a thiol can regenerate the catalytic form through thiol-disulfide exchange.
The finding that these simple alkyl-aryl disulfides are generally less active against E. coli than
S. aureus or B. anthracis may also reflect differences in the thiol-redox buffers of these three
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microbes.13,47 Staphylococcus and Bacillus utilize a coenzyme-A based thiol-redox buffer,
while E. coli uses a glutathione buffer. Consequently, the effects of the aryl alkyl disulfides in
glutathionebased eukaryotic cells would likely also be dampened, which is a question we are
now exploring.
For the past decade, there has been considerable interest in the development of FabH inhibitors
as potential antibacterial agents.48,49 The key role of FabH in Type II fatty acid synthesis, as
well as the unique differences between bacterial and mammalian FAS pathways, make this
protein a desirable target for the selective inhibition of bacterial growth. We are exploring
potential applications of these disulfide inhibitors of FabH as antibacterial agents for lifethreatening bacterial infections.

4. Experimental
4.1. General methods
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Reagents were purchased from Sigma-Aldrich Chemical Company or Acros Chemical
Company. Methanethiolsulfonates were purchased from Toronto Research Chemicals.
Reagents were used without further purification. Solvents were obtained from Fischer
Scientific Company. Thin-layer chromatography (TLC) was carried out using EM Reagent
plates with fluorescence indicator (SiO2-60, F-254). Products were purified by flash
chromatography using J.T. Baker flash chromatography silica gel (40 µm). NMR spectra were
recorded in CDCl3 unless otherwise noted. 13C NMR spectra were proton broad-band
decoupled. Methylene chloride and THF were distilled prior to use. Prior to the preparation of
the disulfides, methanol was purged of oxygen by bubbling nitrogen an inert gas through it for
several minutes.
4.2. m-Nitrobenzenethiol.50
To a solution of m-nitrobenzene disulfide (300 mg, 0.97 mmol) in anhydrous THF (2 mL) was
added solid NaBH4 (140 mg, 3.4 mmol) in small portions. The resulting mixture was stirred
at rt under an inert atmosphere. After 2 hr, the reaction mixture was cooled in an ice bath, then
about 5 mL of icewater was added to the mixture. The resulting mixture was acidified with
HCl (1 M), then extracted with CH2Cl2 (10 mL). The organic layer was then washed with water
(10 mL), then brine (10 mL), dried over MgSO4, and concentrated in vacuo to give the thiol
(248 mg, 83%) as a pale yellow oil. 1H NMR (CDCl3, 400 MHz): δ 8.10 (d, J=2.0 Hz, 1H);
7.97 (dd, J=8.0, 2.0 Hz, 1H); 7.54 (d, J=8.0 Hz, 1H); 7.38 (t, J=8.0 Hz, 1H); 3.68 (s, 1H); 13C
NMR (CDCl3, 100 MHz): δ 134.9, 130.0, 123.9, 120.7.
4.3. o-Nitrobenzenethiol
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Prepared exactly as described above, except that the reaction was allowed to run for 3 h, and
the products required chromatography (silica with hexanes: CH2Cl2) to give the thiol (160 mg,
61%) as a pale yellow flocculent solid. Mp: 44–45 °C. 1H NMR (CDCl3, 400 MHz): δ 8.24
(d, J=8.0 Hz, 1H); 7.42 (d, J=4.0 Hz, 1H); 7.29-7.24 (m, 1H); 4.00 (s, 1H). 13C NMR
(CDCl3, 100 MHz): δ 133.9, 132.2, 126.5, 126.0.
4.4 p-Nitrobenzyl thiol
Thioacetic acid (386 µl, 5.40 mmol) was added to a mixture of 4-nitrobenzyl bromide (600
mg, 2.79 mmol) and anhydrous K2CO3 (380 mg, 2.75 mmol) in acetone (3 ml), and the resulting
mixture was stirred at rt for 2 h under an inert atmosphere. The mix was then partitioned
between CH2Cl2 (10 ml) and water (10 ml). The organic layer was separated, then washed
quickly with saturated aqueous NaHCO3 (10 ml) and brine (10 ml). The organic solution was
concentrated in vacuo, then taken up in methanol (5 ml). Aqueous H2SO4 (50%, 1 ml) was
added, and the solution was heated to reflux for 3h, under N2. The solution was partitioned
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between ether (30 ml) and water (30 ml). The ether layer was washed with water (2×30 ml),
then brine (10 ml). The solution was dried over Na2SO4, then concentrated in vacuo to give
the thiol (317 mg, 67%) as a yellow solid. mp: 49–52 °C. 1H NMR (200 MHz,CDCl3): δ 8.19
(d, J=8.8 Hz, 2H); 7.02 (d, J=8.6 Hz, 2H); 3.82 (d, J=7.8 Hz, 2H); 1.84 (t, J=8.1 Hz, 1H).
4.5. p-Nitrophenethyl thiol
Prepared according to the general procedure described above, except that the reaction time was
45 min. Isolated 170 mg (69%) as a yellow liquid. 1H NMR (200 MHz, CDCl3): δ 8.17 (d,
J=8.8 Hz, 2H); 7.35 (d, J=8.8 Hz, 2H); 3.04 (t, J=7.7 Hz, 2H); 2.84 (dt, J=5.9 Hz, 7.7 Hz, 2H);
1.38 (t, J=5.9 Hz, 1H).
4.6. Synthesis of alkyl aryl disulfides: General procedure
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To a 1.0 M solution of aryl thiol in MeOH (100 µl) was added a solution of alkyl
methanethiolsulfonate in MeOH (105 µl of a 1.0 M solution, 1.05 eq) After stirring at rt under
an inert atmosphere for 1 h, the solutions were treated with a small amount (about 0.3 eq) of
cysteine hydrochloride in order to consume the excess thiosulfonate. The mixture was then
concentrated under reduced pressure. The solid was taken up in CH2Cl2 (1 mL), and the
insoluble material was filtered off. The solution was stirred with Amberlyst-21 resin (weakly
basic), (approx. 0.2 eq, pre-swelled in CH2Cl2) for 3 min. The solution was drawn off of the
resin, quickly passed through a small silica plug using dichloromethane, and concentrated in
vacuo to give the desired product.
4.6.1. 3,4-Difluorophenyl methyl disulfide (1)—9.6 mg (50%) as a colorless oil. 1H
NMR (250 MHz, CDCl3): δ 7.37-7.29 (m, 1H); 7.18-7.00 (m, 2H); 2.34 (s, 3H).
4.6.2 3,4-Dimethylphenyl methyl disulfide (2)—Isolated 9.7 mg (53%) as a colorless
oil. 1H NMR (250 MHz, CDCl3): δ 7.22 (d, J=8.4 Hz, 1H); 7.18 (s, 1H); 7.02 (d, J=7.7 Hz,
1H); 2.70 (s, 3H); 2.19 (s, 3H); 2.18 (s, 3H).
4.6.3. m-Ethoxyphenyl methyl disulfide (3)—Isolated 5.6 mg (28%) as a colorless
oil. 1H NMR (400 MHz, CDCl3): δ 7.21 (t, J=8.0 Hz, 1H); 7.09-7.05 (m, 2H); 6.74 (dd, J=8.0,
1.2 Hz, 1H); 4.04 (q, J=7.1 Hz, 2H); 2.43 (s, 3H); 1.41 (t, J=7.4 Hz, 3H).
4.6.4 o-(Hydroxymethyl)phenyl methyl disulfide (4)—1H NMR (400 MHz, CDCl3): δ
7.73 (d, J=8.8 Hz, 1H); 7.44 (dd, J=6.6, 2.2 Hz, 1H); 7.32-7.24 (m, 2H); 4.83 (d, J=5.2 Hz,
2H); 2.42 (s, 3H); 2.02 (broad t, J=6.0 Hz, 1H).
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4.6.5. Methyl 2-pyridinyl disulfide (5)—1H NMR indicates about 10% of material is
unreacted thiol. 1H NMR (400 MHz, CDCl3): δ 8.46 (d, J=4.4 Hz, 1H); 7.68-7.61 (m, 2H);
7.07 (t, J=6.6 Hz, 1H); 2.49 (s, 3H).
4.6.6. p-Acetamidophenyl methyl disulfide (6)—To a solution of pacetamidobenzenethiol (50 mg, 0.3 mmol) in dry CH2Cl2 (3 ml) was added triethylamine (127
µL, 0.9 mmol, 3 eq.), followed by acetyl chloride (32 µL, 0.45 mmol). The reaction was stirred
at RT for 1 hr, then was diluted with dichloromethane, washed with water, then 5% aq. HCl,
then 5% aq. NaHCO3. Dried over MgSO4, then concentrated in vacuo to give a yellow oil
which solidified on standing. Chromotography (1:1 petroleum ether:ethyl acetate) gave 18 mg
(29%) as a light brown solid. 1H NMR (400 MHz, CDCl3): δ 7.47 (s, 4H); 2.41 (s, 3H); 2.16
(s, 3H).
4.6.7. p-Aminophenyl methyl disulfide (7)—To a solution of p-aminobenzenethiol (125
mg, 1 mmol) in methanol (1 ml) was added methylthio methanesulfonate (94 µl, 1 mmol) in
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a single portion. The reaction was stirred at RT under N2. After 2 hr, the solution was loaded
onto an SCX column and eluted with methanol, followed by 1M ammonia in methanol. The
basic eluents were concentrated in vacuo to a yellow oil. Chromatography (1:1
hexanes:CH2Cl2 with 1% isopropyl amine) yielded 8 (140 mg, 82%) as a pale yellow oil. 1H
NMR (250 MHz, CDCl3): δ 7.28 (d, J=8.6 Hz, 2H); 6.54 (d, J=8.6 Hz, 2H); 3.60 (broad s, 2H);
2.34 (s, 3H). Treatment with HCl/ether gave 5 mg of the HCl salt. Biological testing was
performed on the acid salt. 1H NMR (400 MHz, d6-DMSO): δ 7.46 (broad s, 2H); 7.05 (broad
s, 2H); 2.47 (s, 3H); 2.43 (s, 3H).
4.6.8. p-Nitrophenyl methyl disulfide (8a)—Isolated 15.3 mg (76%) as a yellow oil. 1H
NMR (400 MHz, CDCl3): δ 8.17 (d, J=8.8 Hz, 2H); 7.63 (d, J=8.8 Hz, 2H); 2.46 (s, 3H).
Resynthesis using 10x scale yielded 184 mg (92%) as a slightly oily, bright yellow solid. Mp:
29–32 °C. 13C NMR (100 MHz, CDCl3): δ 126.6, 126.0, 124.7, 124.4, 22.9.
4.6.9. Ethyl p-nitrophenyl disulfide (8b)—1H NMR (400 MHz, CDCl3): δ 8.14 (d, J=8.8
Hz, 2H); 7.64 (d, J=8.8 Hz, 2H); 2.77 (q, J=7.0 Hz, 2H); 1.31 (t, J=7.2 Hz, 3H).
4.6.10. Isopropyl p-nitrophenyl disulfide (8c)—1H NMR (400 MHz, CDCl3): δ 8.14
(d, J=8.8 Hz, 2H); 7.64 (d, J=8.8 Hz, 2H); 3.10 (septuplet, J= 6.5 Hz, 1H); 1.30 (d, J=6.8 Hz,
6H).
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4.6.11. sec-Butyl p-nitrophenyl disulfide (8d)—1H NMR (400 MHz, CDCl3): δ 8.14
(d, J=8.8 Hz, 2H); 7.64 (d, J=8.8 Hz, 2H); 2.88-2.83 (m, 1H); 1.73-1.64 (m, 1H); 1.57-1.50
(m, 1H); 1.27 (d, J=6.8 Hz, 3H); 0.97 (t, J=7.2 Hz, 3H).
4.6.12. p-Nitrophenyl n-propyl disulfide (8e)—1H NMR (400 MHz, CDCl3): δ 8.14 (d,
J=8.8 Hz, 2H); 7.63 (d, J=8.8 Hz, 2H); 2.73 (t, J=7.2 Hz, 2H); 1.68 (tq, J=7.2, 7.6 Hz, 2H);
0.98 (t, J=7.6 Hz, 3H).
4.6.13. n-Butyl p-nitrophenyl disulfide (8f)—1H NMR (400 MHz, CDCl3): δ 8.15 (d,
J=8.0 Hz, 2H); δ 7.64 (d, J=8.8 Hz, 2H); δ 2.95 (t, J=7.4 Hz, 2H); δ 1.65-1.61 (m, 2H); δ
1.42-1.37 (m, 2H); δ 0.88 (t, J=7.2 Hz, 3H).
4.6.14. Methyl o-nitrophenyl disulfide (9a)—Isolated 13.9 mg (69%) as an oily yellow
solid. 1H NMR (400 MHz, CDCl3): δ 8.27-8.23 (m, 2H); 7.69 (t, J=7.4 Hz, 1H); 7.35 (d, J=7.2
Hz, 1H); 2.41 (s, 3H).
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4.6.15. Ethyl o-nitrophenyl disulfide (9b)—Isolated 13.2 mg (62%) as an oily yellow
solid. 1H NMR (400 MHz, CDCl3): δ 8.28 (d, J=8.0 Hz, 1H); 8.24 (d, J=8.0 Hz, 1H); 7.66 (t,
J=7.4 Hz, 1H); 7.33 (t, J=7.6 Hz, 1H); 2.74 (q, J=7.3 Hz, 2H); 1.31 (t, J=7.2 Hz, 3H).
4.6.16. Isopropyl o-nitrophenyl disulfide (9c)—Chromatographed on silica with 3%
dichloromethane in hexanes as eluent. Isolated 13.7 mg (60%) as a yellow oil. 1H NMR (400
MHz, CDCl3): δ 8.28 (d, J=8.8 Hz, 1H); 8.23 (d, J=8.8 Hz, 1H); 7.64 (t, J=7.9 Hz, 1H); 7.31
(t, J=7.6 Hz, 1H); 3.05 (s, J= 6.8 Hz, 1H); 1.31 (d, J=6.8 Hz, 6H).
4.6.17. Butyl o-nitrophenyl disulfide (9d)—Chromatographed on silica with 3%
dichloromethane in hexanes as eluent. Isolated 12.9 mg (54%) as a yellow oil. 1H NMR (400
MHz, CDCl3): δ 8.29 (d, J=8.0 Hz, 1H); 8.22 (d, J=8.8 Hz, 1H); 7.64 (t, J=7.8 Hz, 1H); 7.31
(t, J=8.0 Hz, 1H); 2.86-2.79 (m, 1H); 1.75-1.60 (m, 1H); 1.58-1.50 (m, 1H); 1.28 (d, J=7.2 Hz,
3H); 0.98 (t, J=7.8 Hz, 3H).
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4.6.18. Methyl m-nitrophenyl disulfide (10a)—Isolated 7.6 mg (38%) as a colorless
oil. 1H NMR (400 MHz, CDCl3): δ 8.39 (s, 1H); 8.04 (d, J=6.4Hz, 1H); 7.79 (d, J=8.0 Hz,
1H); 7.49 (t, J=8.0 Hz, 1H); 2.47 (s, 3H).
4.6.19. Ethyl m-nitrophenyl disulfide (10b)—Isolated 7.7 mg (36%) as a colorless
oil. 1H NMR (400 MHz, CDCl3): δ 8.41 (s, 1H); 8.02 (d, J=7.2 Hz, 1H); 7.80 (d, J=7.2 Hz,
1H); 7.47 (t, J=7.2 Hz, 1H); 2.78 (q, J=7.3 Hz, 2H); 1.32 (t, J=7.2 Hz, 3H).
4.6.20. Isopropyl m-nitrophenyl disulfide (10c)—Isolated 17.0 mg (75%) as a colorless
oil. 1H NMR (400 MHz, CDCl3): δ 8.41 (s, 1H); 8.01 (d, J=8.0 Hz, 1H); 7.80 (d, J=7.2 Hz,
1H); 7.46 (t, J=7.2 Hz, 1H); 3.09 (septet, J=6.8 Hz, 1H); 1.30 (d, J=6.8 Hz, 6H).
4.6.21. Butyl m-nitrophenyl disulfide (10d)—Isolated 12.6 mg (52%) as a colorless
oil. 1H NMR (400 MHz, CDCl3): δ 8.42 (s, 1H) 8.00 (d, J=8.0 Hz, 1H); 7.80 (d, J=8.0 Hz,
1H); 7.45 (t, J=8.0 Hz, 1H); 2.88-2.83 (m, 1H); 1.73-1.68 (m, 1H); 1.57-1.50 (m, 1H); 1.28 (d,
J=7.2 Hz, 3H); 0.97 (t, J=7.2 Hz, 3H).
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4.6.22. Methyl 4-nitrobenzyl disulfide (11)—Prepared according to the general
procedure outlined above for the aryl alkyl disulfides. Following chromatography (3:1
hexanes:CH2Cl2), 3.1 mg (5%) was obtained as a pale yellow solid. 1H NMR (200 MHz,
CDCl3): δ 8.20 (d, J=8.7 Hz , 2H); 7.51 (d, J=8.6 Hz, 2H); 3.94 (s, 2H); 2.15 (s, 3H).
4.6.23. Methyl 2-(p-nitrophenethyl) disulfide (12)—Obtained 9.7 mg (15%) as a pale
yellow oil. 1H NMR (200 MHz, CDCl3): δ 8.17 (d, J=8.0 Hz, 2H); 7.37 (d, J=8.0 Hz, 2H);.
3.19-2.85 (m, 4H); 2.43 (s, 3H). MS (EI) m/z: 229 (M+).
4.7. General microbiological methods
S. aureus (ATCC 25923) and MRSA (ATCC 43300) were purchased from ATCC sources.
Bacillus bacteria from Sterne spore vaccine was purchased from Colorado Serum Co., Denver.
CO.
4.7.1. Culture preparation—From a freezer stock in tryptic soy broth (Difco Laboratories,
Detroit, MI) and 20 % glycerol, a culture of each microorganism was transferred with a sterile
Dacron swab to Trypticase® Soy Agar (TSA) plates (Becton-Dickinson Laboratories,
Cockeysville, MD), streaked for isolation, and incubated at 37 °C for 24 h. A 108 standardized
cell count suspension was then made in sterile phosphate-buffered saline (pH 7.2) and swabbed
across fresh TSA plates.
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4.7.2. Antimicrobial testing: Kirby-Bauer method—Sterile saline (5 mL) was
inoculated with a swab of bacteria, then the concentration was adjusted to 0.5 McFarland
standard. Bacterial solution was then streaked across a TSA plate to give an even lawn of
bacteria. 1–30 µL sterile pipet tips were used to drill 6 mm wells into the agar plate, then 20
µL of 1 mg/mL drug in DMSO was added to the well. Plates were inoculated overnight at 37°
C.
4.7.3. Agar dilution minimal inhibitory concentration (MIC) assay—A stock
solution of 1 mg/mL of each disulfide was prepared in DMSO. 1.5 mL of freshly-prepared
Mueller-Hinton agar was added to each well of a 24-well plate, and to each well was then added
a specified amount of the disulfide test solution in order to a give a final drug concentration of
256 mg/mL down to 0.125 ug/mL. One well within each series received 0.1 mL of DMSO as
a blank. The contents of each well were thoroughly stirred to evenly distribute the antimicrobial
solution within the agar. Once the agar completely solidified, 10 µL of sterile saline containing
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0.5 McFarland standard of the test bacteria was pipeted on top of each well and the plates were
then incubated for 24 hours at 37° C. Bacterial growth was assessed by visual observation of
growth.
4.7.4 FabH enzyme assay—FabH assays were carried out using a standard coupled
trichloroacetic acid precipitation assay which determines the rate of formation of radiolabeled
3-ketoacyl ACP from malonyl ACP and radiolabeled acetyl CoA. In this coupled assay
Streptomyces glauscescens FabD is used to generate the malonyl ACP substrate from malonyl
CoA and Streptomyces glauscescens ACP. For inhibition studies, A standard 20 µL reaction
mixture of ecFabH (2 pmol of monomer, 100 nM) and test compound (0.02 nmol, 1µM for
compounds 15a and 15b; 0.1 nmol, 5 µM for compounds 8a–f) in 50 mM sodium phosphate
buffer (pH 7.4) was incubated at room temperature for 15 min prior to addition to a solution
of [1-14C]acetylCoA (0.8 nmole, 40 µM) and MACP (0.2 nmole, 10 µM). The inhibition was
measures using standard FabH assay.51 The % inhibition was determined my measuring FabH
activity in the presence of test compound relative to a negative control that has no inhibitor
(100% activity). The assay was run in duplicate.
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Figure 1.

Antibacterially-active sulfenylating agents.
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Figure 2.

Naturally-occurring disulfide and trisulfide antibacterials from garlic.
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Figure 3.

p-Nitrobenzyl and p-nitrophenethyl disulfides 11 and 12.
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Figure 4.

Methyl p-nitrophenyl sulfide (13) and Ellman’s reagent (14).
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Figure 5.

N-Alkylthio β-lactams (15a and 15b).
FabH inhibitor disulfide 16.
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Methyl-coenzyme A mixed disulfide.
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Figure 6.
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Scheme 1.

Sulfenylation of coenzyme A by N-thiolated β-lactams.
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Scheme 2.

Synthesis of aryl methyl disulfides 1–8.
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Diameter of zone (mm)

11

1
10

2
9

3
14

4
23

5
20

6
0

7
35

8

Zones of bacterial growth inhibition data from Kirby-Bauer testing of disulfides 1–8 against S.aureus (ATCC 25923) on agar plates
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Table 2

Zones of Inhibition (on agar plates) and MIC values (in broth) for aryl disulfides 8a–f, 9a–d, and 10a–d against S.
aureus, MRSA, and B. anthracis.
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Cpd

Alkyl R

S. aureus
(ATCC 25923)

MRSA
(ATCC 43300)

B.anthracis

8a

methyl

8b

ethyl

8c

isopropyl

8d

sec-butyl

8e

n-propyl

8f

n-butyl

9a

methyl

9b

ethyl

9c

isopropyl

9d

sec-butyl

10a

methyl

10b

ethyl

10c

isopropyl

10d

sec-butyl

35 mm
16 ug/ml
54 mm
1 ug/ml
85 mm
<0.125 ug/ml
68 mm
0.8 ug/ml
43 mm
16 ug/ml
53 mm
1 ug/ml
36 mm
16 ug/ml
45 mm
8 ug/ml
85 mm
<0.125 ug/ml
45 mm
8 ug/ml
37 mm
16 ug/ml
40 mm
16 ug/ml
31 mm
16 ug/ml
24 mm
32 ug/ml
33 mm
0.03 ug/ml
27 mm
0.25 ug/ml

23 mm
32 ug/ml
38 mm
16 ug/ml
75 mm
<0.125 ug/ml
54 mm
1.0 ug/ml
38 mm
16 ug/ml
28 mm
32 ug/ml
15 mm
64 ug/ml
12 mm
64 ug/ml
38 mm
16 ug/ml
22 mm
32 ug/ml
26 mm
32 ug/ml
28 mm
32 ug/ml
20 mm
32 ug/ml
20 mm
32 ug/ml
14 mm
64 ug/ml
22 mm
0.5 ug/ml

54 mm
1 ug/ml
67 mm
0.25ug/ml
71 mm
0.125ug/ml
62 mm
0.5 ug/ml
57 mm
1 ug/ml
52 mm
1 ug/ml
43 mm
8 ug/ml
40 mm
8 ug/ml
54 mm
1 ug/ml
41 mm
8 ug/ml
31 mm
16 ug/ml
35 mm
16 ug/ml
27 mm
32 ug/ml
23 mm
32 ug/ml
nt
nt
nt
nt

Penicillin G
Vancomycin

The top value for each compound and microbe is the average diameter of growth inhibition (3 trials) produced after 24 h of incubation using 20 ug of test
compound (in DMSO). The lower value is the minimum inhibitory concentration (MIC) of drug (in µg/mL), the lowest concentration of compound in the
agar where bacterial growth is completely inhibited. MIC values were determined by serial dilution in 24-well plates according to NCCLS protocols.38
nt =not tested.
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Table 3

Comparison of the minimum inhibitory concentration (MIC) values of p-nitrophenyl alkyl disulfides 8a–f against E.
coli in broth.
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Compound

8a
8b
8c
8d
8e
8f

E. coli
(ATCC 23590)
16 ug/ml
16 ug/ml
96 ug/ml
128 ug/ml
64 ug/ml
96 ug/ml
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Table 4

Percent inhibitiona of FabH derived from E. coli by disulfides 8a–f.
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Compound

ecFabH (%)

8a
8b
8c
8d
8e
8f

94
98
98.5
96
91
93

a

Measured as the percent decrease in activity of FabH in the presence of 5 µM of disulfides 8a–f, as compared to the same enzyme in the absence of the
disulfide.

NIH-PA Author Manuscript
NIH-PA Author Manuscript

